Welcome to our dedicated page for Quantum Cyber N.V. SEC filings (Ticker: QUCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quantum Cyber N.V. (QUCY) SEC filings document a Nasdaq-listed issuer whose public record includes both its former Mainz Biomed N.V. identity and its newer autonomous defense technology focus. The company’s quarterly reports and 8-K filings are important because they describe material agreements, license arrangements, property acquisition activity, capital structure matters, governance items, and operating and financial results.
For QUCY, quarterly reports can show how the company reports expenses, liabilities, share issuance, and historical operating results. Recent quarterly disclosure describes the exclusive LightShift license for quantum photonic array technology, the related accounting treatment, and the company’s issued ordinary shares. Earlier quarterly disclosure also discusses ColoAlert sales and the wind down of the prior colorectal cancer screening sales and marketing team.
Material 8-K filings are especially relevant for Quantum Cyber because they have covered the Project LightShift intellectual property license, an amendment involving BP United manufacturing and consulting services, termination of an at-the-market issuance sales agreement, a change in independent registered public accounting firm, investor presentation materials, and the Bridgeport property acquisition involving Quantum Drones Corporation and Arcade Realty LLC.
Annual reports, proxy statements, and Form 4 insider transaction reports, when available, add context on risk factors, governance, executive compensation, ownership changes, and insider trading activity. Plain-language filing summaries can help readers separate core disclosures from legal formatting, with particular attention to 10-Q reports, 10-K annual reports, Form 4 transactions, and 8-K material event filings tied to QUCY’s defense technology and manufacturing strategy.
Quantum Cyber N.V. (QUCY) reported a sharp increase in losses while executing a major strategic pivot. For the six months ended June 30, 2026, the company generated no revenue from continuing operations and recorded a net loss of $16.1 million, nearly double the prior-year period, driven by higher R&D and stock-based compensation tied to its new quantum drones and cybersecurity focus.
Total operating expenses from continuing operations rose to $12.4 million, including $4.3 million of in‑process R&D expense for a quantum antenna license from LightShift and increased general and administrative costs for new leadership and staff. The legacy colorectal cancer screening business was classified as discontinued operations and largely exited via asset sales totaling $1.6 million.
Liquidity improved: cash increased to $13.5 million from $0.9 million, mainly from $22.2 million of financing inflows, including preferred share issuances and warrant exercises. However, with an accumulated deficit of about $121.0 million and continued operating cash use of $9.9 million in the half‑year, management disclosed that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and its plans depend on executing the new business model and securing further funding.
Quantum Cyber N.V. reported that Chief Financial Officer William J. Caragol received a grant of stock options on August 11, 2026. The award covers 212,500 Stock Options, each exercisable for one Ordinary Share at a conversion or exercise price of $1.37 per share and expiring on August 11, 2036. According to the grant terms, these options will vest in eighteen substantially equal monthly installments beginning on the grant date, subject to Mr. Caragol continuing to provide services through each applicable vesting date.
Quantum Cyber N.V. received a Schedule 13G indicating that BP United Inc. and Alexander Gurevich together report beneficial ownership of Ordinary Shares, nominal value (euro)0.01 per share. BP United reports beneficial ownership of 2,174,834 shares, representing 7.9% of the Ordinary Shares outstanding.
Alexander Gurevich reports beneficial ownership of 2,718,543 shares, or 9.8% of the class, including shares held through BP United. The ownership percentages are based on 27,647,833 Ordinary Shares outstanding as of July 8, 2026. The reporting persons disclaim beneficial ownership of each other’s directly held shares and state that the filing does not constitute an admission of group status.
Quantum Cyber N.V. discloses that Chief Executive Officer and ten percent owner David E. Lazar converted several classes of Preferred Shares into Ordinary Shares after stockholder approval on April 22, 2026, permitting conversion for no additional consideration at his option.
On August 5, 2026, he converted 1,000,000 Series A, 1,000,000 Series B, 1,000,000 Series C, and 124,700 Series D Preferred Shares into Ordinary Shares, leaving 875,300 Series D Preferred Shares in his direct holdings.
David E. Lazar reports updated beneficial ownership in Quantum Cyber N.V. (formerly Mainz Biomed N.V.), holding 477,000,000 Ordinary Shares, which represents 94.3% of the company’s Ordinary Shares. He has sole voting and sole dispositive power over all reported shares.
His reported holdings comprise 55,057,500 issued Ordinary Shares, 196,942,500 Ordinary Shares issuable upon conversion of Series D Preferred Shares, and 225,000,000 Ordinary Shares issuable upon conversion of Series E Preferred Shares. On August 5, 2026, he converted 1,000,000 Series A, 1,000,000 Series B, 1,000,000 Series C, and 124,700 Series D Preferred Shares into 9,000,000, 9,000,000, 9,000,000, and 28,057,500 Ordinary Shares, respectively, for no additional consideration. The ownership percentage is calculated using 84,068,192 Ordinary Shares outstanding as of August 7, 2026, plus the Series D and Series E conversion shares.
O'Rourke Peter reported acquisition or exercise transactions in this Form 4 filing.
Quantum Cyber N.V. director Peter O'Rourke received a grant of 191,860 stock options on July 22, 2026, each exercisable at 1.1400 per share for Ordinary Shares and expiring August 3, 2036. The amended report corrects the transaction date, option and underlying share quantities, and post-transaction beneficial ownership, and now shows 191,860 derivative securities held directly. The options vest in eighteen substantially equal installments on each monthly anniversary of the grant date, contingent on O'Rourke continuing to provide services.
Quantum Cyber N.V. director Natan David received a grant of Stock Options (Right to Buy) covering 191,860 Ordinary Shares at an exercise price of 1.1400 per share, expiring 2036-08-03. The options vest in eighteen substantially equal monthly installments, contingent on continued service, and the corrected report shows 191,860 options beneficially owned after the transaction.
Quantum Cyber N.V. filed an amended Form 4 reporting that Chief Financial Officer William J. Caragol received a grant of 212,500 stock options to purchase Ordinary Shares at an exercise price of $1.14 per share. The options expire on 2036-08-03 and vest in eighteen substantially equal monthly installments from the grant date, contingent on continued service; the amendment corrects the previously reported transaction date.
Quantum Cyber N.V. director Louis R. Buffalino received a grant of 425,000 Stock Options (Right to Buy) on July 22, 2026. Each option is exercisable for one Ordinary Share at an exercise price of $1.14 per share and expires on August 3, 2036. The amended report corrects the date of the reported transaction. The Stock Options vest in eighteen substantially equal monthly installments from the grant date, subject to his continued service, leaving 425,000 options reported as held directly after the grant.
Quantum Cyber N.V. director Ben-Tzvi Avraham received a grant of 112,859 Ordinary Shares on July 22, 2026 at $0.00 per share, increasing his direct holdings to 252,000 shares. This amended Form 4 corrects the originally reported transaction date, shares acquired, and post-transaction beneficial ownership.